Last week, the American Academy of Pediatrics and the Children’s Hospital Association reported that one in four new COVID cases are in children, while the FDA inches closer to approving an emergency use vaccine in children ages 12 and under. Dr. Daniel Fagbuyi, emergency physician, joined Cheddar to discuss why the FDA’s process for approving an emergency use vaccine in kids is painstakingly slow. He noted that children’s immune systems are not like adults, and while they are more robust, measuring proper dosage and observing effects on the body is time consuming.